Bisphosphonates for osteoporosis in primary biliary cirrhosis

Rudić, Jelena S; Giljača, Vanja; Krstić, Miodrag; Bjelaković, Goran; Gluud, Christian

doi:10.1002/14651858.cd009144.pub2

Cited by 19 publications

(14 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 133 Severity of low bone mass is associated with morbidity in PBC due to fractures, pain, and skeletal deformity. 135 Severe bone disease fortunately appears to be decreasing in PBC patients, perhaps due to improvements in MBD screening and therapy. 4 …”

Section: Clinical Consequences Of Pbc and Psc Relating To Women's Heamentioning

confidence: 99%

Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective

Beery

Vaziri

Forouhar

2014

JCTH

View full text Add to dashboard Cite

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are two major types of chronic cholestatic liver disease. Each disorder has distinguishing features and variable progression, but both may ultimately result in cirrhosis and hepatic failure. The following offers a review of PBC and PSC, beginning with a general overview of disease etiology, pathogenesis, diagnosis, clinical features, natural course, and treatment. In addition to commonly associated manifestations of fatigue, pruritus, and fat-soluble vitamin deficiency, select disease-related topics pertaining to women's health are discussed including metabolic bone disease, hyperlipidemia and cardiovascular risk, and pregnancy-related issues influencing maternal disease course and birth outcomes. This comprehensive review of PBC and PSC highlights some unique clinical considerations in the care of female patients with cholestatic liver disease.

show abstract

Section: Clinical Consequences Of Pbc and Psc Relating To Women's Heamentioning

confidence: 99%

Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective

Beery

Vaziri

Forouhar

2014

JCTH

View full text Add to dashboard Cite

show abstract

“…Bisphosphonate (BPs) are widely used for the prevention and treatment of a range of bone conditions, including postmenopausal osteoporosis, Paget disease, hypercalcemia in malignancies, and osteolytic bone metastases of cancer or multiple myeloma [1,2]. BPs can be administered orally and intravenously in a wide range of doses, dosing intervals, and duration of administration [1]. The biologic action of BPs is to suppress farnesyl pyrophosphate synthase in the mevalonate biosynthetic pathway and inhibit the resorption of bone via the inactivation of osteoclasts [3].…”

Section: Introductionmentioning

confidence: 99%

“…The biologic action of BPs is to suppress farnesyl pyrophosphate synthase in the mevalonate biosynthetic pathway and inhibit the resorption of bone via the inactivation of osteoclasts [3]. Although this action accounts for the preventive or therapeutic efficacy of these agents, it also accounts for their uncommon skeletal-related events (SRE) or adverse effects [1,2]. In particular, cases of osteonecrosis of the jaw (ONJ) have been reported as possible adverse effect of BPs since 2003 [4].…”

Section: Introductionmentioning

confidence: 99%

Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw: Focus on Risk, Prevention and Treatment

Yamazaki¹,

Takahashi²

2014

RRCT

View full text Add to dashboard Cite

Bisphosphonates (BPs) are widely used for the treatment of a range of conditions involving bone, such as osteoporosis and bone metastases of cancer, and their efficacy has been confirmed. Nevertheless, a first case of bisphosphonate- related osteonecrosis of the jaw (BRONJ) as an adverse effect of BP treatment was reported in 2003, and several clinical studies since then have elaborated the risk, prevention and treatment of BRONJ or bisphosphonate-related osteomyelitis of the jaw (BROMJ). However, effective decision making on BP risk is hampered by a lack of accurate information for patients, physicians or dentists. Furthermore, the narrow definition of BRONJ used to date has precluded the wider development of clinical research on risk. In this review, we discuss current issues in BROMJ, with a focus on risk, prevention and treatment. In particular, we reconsider the definition of BRONJ from the standpoint of clinical evidence. Finally, we propose a new strategy for the treatment of BROMJ.

show abstract

“…Oral bisphosphonates (BPs) are useful in the treatment of various bone metabolic diseases, such as postmenopausal osteoporosis or Paget disease [1], but their use is associated with the occurrence of osteonecrosis of the jaw (ONJ), also known as osteomyelitis of the jaw (OMJ), as an adverse effect. This condition is considered refractory and causes a decrease in the quality of life in patients.…”

Section: Introductionmentioning

confidence: 99%

Risk Factors and Indices of Osteomyelitis of the Jaw in Osteoporosis Patients: Results from a Hospital-Based Cohort Study in Japan

et al. 2013

View full text Add to dashboard Cite

BackgroundSeveral studies have reported osteomyelitis of the jaw (OMJ) as a side effect of bisphosphonates (BPs), and the risk of oral BPs has been recently clarified. However, other systemic risk factors of OMJ remain unclear. Importantly, the possibility of risk classification based on the clinical characteristics of patients has not been explored. Here, we clarified risk factors of OMJ and evaluate the predictive accuracy of risk indices in osteoporosis patients.MethodsWe performed sub-analysis using a database developed for a retrospective cohort study in patients taking medications for osteoporosis at Kyoto University Hospital. Risk indices for OMJ were constructed using logistic regression analysis, and odds ratios (OR) for OMJ cases and 95% confidence intervals (CI) were estimated. Potential risk factors included in the statistical analysis were age; sex; diabetes; use of oral BPs, corticosteroids, cancer chemotherapy, antirheumatic drugs, and biologic agents; and their interactions. Risk indices were calculated by the sum of potential risk factors of an individual patient multiplied by the regression coefficients. The discriminatory power of the risk indices was assessed by receiver operating characteristic (ROC) analysis.ResultsIn analysis of all patients, oral BPs (OR: 4.98, 95% CIs: 1.94-12.75), age (OR: 1.28, 95% CI: 1.06-1.60) and sex-chemotherapy interaction (OR: 11.70, 95% CI: 1.46-93.64) were significant risk factors of OMJ. Areas under the ROC curves of these risk indices provided moderate sensitivity or specificity regardless of group (0.683 to 0.718).ConclusionsOur data suggest that oral BP use, age, and sex-chemotherapy are predictors of OMJ in osteoporosis patients. The risk indices are moderately high, and allow the prediction of OMJ incidence.

show abstract

Bisphosphonates for osteoporosis in primary biliary cirrhosis

Cited by 19 publications

References 82 publications

Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective

Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective

Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw: Focus on Risk, Prevention and Treatment

Risk Factors and Indices of Osteomyelitis of the Jaw in Osteoporosis Patients: Results from a Hospital-Based Cohort Study in Japan

Contact Info

Product

Resources

About